PDF(Sci-hub)
Abstract：
The treatment efficacy of a nicotine vaccine largely relies on its ability to induce high titers of nicotine-specific antibodies. Due to its strong immune-potentiating effects, aluminum salt (Alum) has been commonly used as an adjuvant in various nicotine vaccine formulations. In this study, we attempted to improve the immunological performance of a hybrid nanoparticle-based nicotine vaccine (NanoNicVac) by co-administering it with Alum. It was found that Alum severely restricted the release of NanoNicVac at the site of injection. Moreover, Alum damaged the hybrid structure of the vaccine. In the animal trial, mice immunized with NanoNicVac alone achieved an anti-nicotine IgG titer of 3.5 ± 0.2 × 104 after three injections. Unexpectedly, Alum with quantities of 125, 250, 500, and 1000 μg did not enhance the immunogenicity of NanoNicVac. In addition, Alum did not improve the ability of the vaccine to reduce the entry of nicotine into the brain.
摘要：
尼古丁疫苗的治疗功效很大程度上依赖于其诱导高滴度的尼古丁特异性抗体的能力。由于其强大的免疫增强作用，铝盐(明矾)通常用作各种尼古丁疫苗制剂中的佐剂。在这项研究中,我们试图通过与明矾共同给药,来改善基于混合纳米颗粒的尼古丁疫苗(NanoNicVac)的免疫学性能.发现明矾严重限制了NanoNicVac在注射部位的释放。此外，明矾破坏了疫苗的杂种结构。在动物试验中,单独用NanoNicVac免疫的小鼠在三次注射后获得3.5±0.2×104的抗尼古丁IgG滴度。出乎意料的是,具有125、250、500和1000μg的量的明矾不增强NanoNicVac的免疫原性。此外,明矾并没有提高疫苗减少尼古丁进入大脑的能力。
